Cytoreductive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy: a Bibliographic Review

Overview

Journal World J Urol

Specialty Urology

Date 2017 Jul 14

PMID 28702843

Citations 5

Authors

Oscar Rodriguez Faba

Sabine D Brookman-May

Estefania Linares

Alberto Breda

Francesca Pisano

Jose Daniel Subiela

Francesco Sanguedolce

Maurizio Brausi

Joan Palou

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC), against a background of lack of evidence following the introduction of targeted therapy.

Methods: A literature review was performed in January 2017 using the MEDLINE/PubMed and EMBASE databases. The PRISMA guidelines were followed for conduct of the study. Two authors independently screened the 270 papers retrieved from the search, and the finally selected publications were identified by consensus between the two reviewers. A total of 55 studies were included in the present review.

Results: Globally, the indications for CN have decreased over recent years. Although current guidelines consider CN an adequate option in selected patients based on prospective studies in the cytokine era, evidence for CN in the era of targeted therapy is based on retrospective studies only.

Conclusions: The results of ongoing prospective studies are still awaited. Retrospective data suggest that young male patients with oligometastatic disease and a good performance status can be considered suitable surgical candidates who may benefit from CN.

Citing Articles

Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.

Napolitano L, Manfredi C, Cirillo L, Fusco G, Passaro F, Abate M Medicina (Kaunas). 2023; 59(4).

PMID: 37109725 PMC: 10143323. DOI: 10.3390/medicina59040767.

Renal cell carcinoma: standards and controversies.

Klatte T, Stewart G World J Urol. 2018; 36(12):1889-1890.

PMID: 30209553 DOI: 10.1007/s00345-018-2490-5.

Safe Resection of Renal Cell Carcinoma with Liver Invasion Using Liver Hanging Technique Supported by Preoperative Portal Vein Embolization.

Fujii M, Kamimura T, Tsukino H, Furukoji E, Sakae T, Yano K Case Rep Urol. 2018; 2018:5139034.

PMID: 30050722 PMC: 6046184. DOI: 10.1155/2018/5139034.

Epidemiology and screening for renal cancer.

Rossi S, Klatte T, Usher-Smith J, Stewart G World J Urol. 2018; 36(9):1341-1353.

PMID: 29610964 PMC: 6105141. DOI: 10.1007/s00345-018-2286-7.

Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.

Klatte T, Fife K, Welsh S, Sachdeva M, Armitage J, Aho T World J Urol. 2017; 36(3):417-425.

PMID: 29256020 DOI: 10.1007/s00345-017-2154-x.

References

Adibi M, Thomas A, Borregales L, Matin S, Wood C, Karam J . Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol. 2015; 33(12):528-37. DOI: 10.1016/j.urolonc.2015.10.003. View

Thorstenson A, Bergman M, Scherman-Plogell A, Hosseinnia S, Ljungberg B, Adolfsson J . Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol. 2014; 48(3):231-8. DOI: 10.3109/21681805.2013.864698. View

Heng D, Wells J, Rini B, Beuselinck B, Lee J, Knox J . Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014; 66(4):704-10. DOI: 10.1016/j.eururo.2014.05.034. View

Flanigan R, Salmon S, Blumenstein B, Bearman S, Roy V, McGrath P . Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2002; 345(23):1655-9. DOI: 10.1056/NEJMoa003013. View

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M . EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67(5):913-24. DOI: 10.1016/j.eururo.2015.01.005. View

Lughezzani G, Capitanio U, Jeldres C, Isbarn H, Shariat S, Arjane P . Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. Cancer. 2009; 115(24):5680-7. DOI: 10.1002/cncr.24682. View

Calvo E, Schmidinger M, Heng D, Grunwald V, Escudier B . Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev. 2016; 50:109-117. DOI: 10.1016/j.ctrv.2016.09.002. View

Heng D, Xie W, Regan M, Harshman L, Bjarnason G, Vaishampayan U . External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14(2):141-8. PMC: 4144042. DOI: 10.1016/S1470-2045(12)70559-4. View

Abern M, Scosyrev E, Tsivian M, Messing E, Polascik T, Dudek A . Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res. 2014; 34(5):2405-11. View

10.

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

11.

Marcus S, Choyke P, Reiter R, Jaffe G, Alexander R, Linehan W . Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol. 1993; 150(2 Pt 1):463-6. DOI: 10.1016/s0022-5347(17)35514-3. View

12.

Gershman B, Thompson R, Moreira D, Boorjian S, Lohse C, Costello B . Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. J Urol. 2016; 197(3 Pt 1):574-579. DOI: 10.1016/j.juro.2016.09.074. View

13.

Li H, Samawi H, Heng D . The use of prognostic factors in metastatic renal cell carcinoma. Urol Oncol. 2015; 33(12):509-16. DOI: 10.1016/j.urolonc.2015.08.003. View

14.

Tsao C, Small A, Moshier E, Gartrell B, Wisnivesky J, Sonpavde G . Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer. 2012; 10(3):159-63. PMC: 4744481. DOI: 10.1016/j.clgc.2012.03.008. View

15.

Fisher R, COLTMAN Jr C, Doroshow J, Rayner A, Hawkins M, Mier J . Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988; 108(4):518-23. DOI: 10.7326/0003-4819-108-4-518. View

16.

Choueiri T, Xie W, Kollmannsberger C, North S, Knox J, Lampard J . The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2010; 185(1):60-6. DOI: 10.1016/j.juro.2010.09.012. View

17.

Conti S, Thomas I, Hagedorn J, Chung B, Chertow G, Wagner T . Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2013; 134(9):2245-52. PMC: 3969398. DOI: 10.1002/ijc.28553. View

18.

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

19.

Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27(34):5794-9. DOI: 10.1200/JCO.2008.21.4809. View

20.

Bex A, Ljungberg B, van Poppel H, Powles T . The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016. Eur Urol. 2016; 70(6):901-905. DOI: 10.1016/j.eururo.2016.07.005. View